ClinicalThought
View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this podcast, Spencer H. Durham, PharmD, BCPS, BCIDP; Stefan Gravenstein, MD, MPH; and Barbara Resnick, PhD, CRNP, discuss risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults. Following their dialogue, the faculty field questions from healthcare professionals.
Presenters:
Spencer H. Durham, PharmD, BCPS, BCIDP
Associate Clinical Professor of Pharmacy Practice
Director, Alumni & Professional Affairs Clinical Affairs & Outreach
Auburn University Harrison School of Pharmacy
Auburn, Alabama
Stefan Gravenstein, MD, MPH
Director
Division of Geriatrics and Palliative Medicine
The Warren Alpert Medical School of Brown University
Providence, Rhode Island
Barbara Resnick, PhD, CRNP
Professor
School of Nursing
University of Maryland
Nurse Practitioner
Roland Park Place
Baltimore, Maryland
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Expert commentary on updates in vaccine development for RSV, from Dr Angela Branche and Clinical Care Options (CCO)
Angela Branche, MD
Released: April 7, 2022
Expert commentary on addressing barriers to vaccine uptake in older individuals, from Dr Barbara Resnick and Clinical Care Options (CCO)
Barbara Resnick, PhD, CRNP
Released: January 12, 2022
Dr David E. Griffith describes the complex role of in vitro susceptibility testing in the management of NTM lung disease, from Clinical Care Options (CCO)
David E. Griffith, MD
Released: December 1, 2021
Dr Princy N. Kumar describes the safety monitoring required of first-line treatment for nontuberculous mycobacterial lung disease, from Clinical Care Options (CCO)
Princy N. Kumar, MD, FIDSA, MACP
Released: November 30, 2021
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.